Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA

Key Points

• Walleye Capital initiated a $1.53 million position in Savara, buying 248,720 shares, while institutional investors collectively own 87.93% of the company.
• Analyst sentiment is mixed: Savara carries a “Moderate Buy” consensus rating with a $10.14 average price target, despite recent sell-rating downgrades from Weiss Ratings and Wall Street Zen.
• Savara reported a quarterly loss of $0.16 per share, missing the $0.14 consensus estimate, and analysts expect continued losses, including projected full-year EPS of negative $0.62.

Walleye Capital LLC acquired a new position in Savara Inc. (NASDAQ:SVRA - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 248,720 shares of the company's stock, valued at approximately $1,532,000. Walleye Capital LLC owned approximately 0.12% of Savara as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in SVRA. Swedbank AB increased its stake in Savara by 54.5% in the 4th quarter. Swedbank AB now owns 850,000 shares of the company's stock worth $5,126,000 after acquiring an additional 300,000 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Savara by 96.5% during the 1st quarter. Renaissance Technologies LLC now owns 652,672 shares of the company's stock valued at $3,564,000 after acquiring an additional 320,572 shares during the last quarter. F m Investments LLC boosted its position in shares of Savara by 56.5% during the 4th quarter. F m Investments LLC now owns 678,813 shares of the company's stock valued at $4,093,000 after acquiring an additional 245,100 shares during the last quarter. Nan Fung Trinity HK Ltd. purchased a new position in shares of Savara during the fourth quarter worth about $10,182,000. Finally, Orbimed Advisors LLC purchased a new position in shares of Savara during the first quarter worth about $3,467,000. Institutional investors own 87.93% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th. Wall Street Zen lowered shares of Savara from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, Oppenheimer assumed coverage on shares of Savara in a research note on Friday, April 24th. They issued an "outperform" rating and a $11.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $10.14.

Key Stories Impacting Savara

Here are the key news stories impacting Savara this week:

• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $0.62 from a loss of $0.59, below the current consensus estimate of a $0.57 loss. Quarterly estimates were also reduced to losses of $0.16 for the third quarter and $0.15 for the fourth quarter.
• Negative Sentiment: The firm cut its 2027 EPS forecast to a loss of $0.37 from $0.34 and its 2028 forecast to a loss of $0.06 from $0.04, indicating continued operating losses over the next several years.
• Negative Sentiment: Longer-term estimates were also reduced: 2029 EPS was lowered to $0.09 from $0.11, while 2030 EPS was cut to $0.37 from $0.39. Although these forecasts still point to eventual profitability, the reductions weaken the near- and long-term earnings outlook.
• Neutral Sentiment: The revisions follow Savara’s recent quarterly results, in which the company reported a $0.16-per-share loss versus the $0.14 loss analysts expected. Investors may therefore remain focused on cash usage, execution and progress toward commercialization.

Savara Trading Up 2.1%

Shares of SVRA stock opened at $5.38 on Friday. The company has a quick ratio of 13.47, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The business has a 50-day moving average price of $5.65 and a two-hundred day moving average price of $5.48. Savara Inc. has a 12-month low of $2.92 and a 12-month high of $7.01. The firm has a market cap of $1.11 billion, a P/E ratio of -9.28 and a beta of 0.29.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). Equities analysts anticipate that Savara Inc. will post -0.62 EPS for the current fiscal year.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source